ArsenalBio announced the formation of a multi-year discovery collaboration with Bristol Myers Squibb to advance next-generation T cell therapies for the treatment of solid tumors. ArsenalBio will be responsible for discovering and building preclinical candidates against multiple targets, and Bristol Myers Squibb will have the option to obtain an exclusive worldwide license to develop and commercialize preclinical candidates. Following exercise of the option, Bristol Myers Squibb would be solely responsible for developing and commercializing the licensed candidates. Through the multi-year collaboration, ArsenalBio will deploy its full stack of synthetic biology compositions to build programmable cell therapy product candidates, composed of its PrimeR™ logic gates, CARchitecture™ derived gene expression controls, and CellFoundry™ mediated nonviral manufacturing. Combined, these integrated circuit-modified T cells offer the promise of improved outcomes for patients.